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Abstract
Background: Breast cancer is the most common cancer and cause of deaths in women around
the world. Oncogene amplification usually occurs late in tumor progression and correlates well
with aggressiveness of tumor. In fact the function of the S100A4 protein and its role in metastasis
is unclear at present. The purpose of the study was to determine the expression of S100A4 protein
in the invasion status and metastatic potential of breast cancer by using tissue microarray and to
determine its role in breast cancer based on the expression of S100A4 gene product.
Methods:  S100A4 protein expression was examined by immunohistochemistry (IHC) using
commercially available tissue microarray containing malignant and normal breast tissue cores from
216 patients.
Results: S100A4 was absent in normal breast tissues while positive in 45.1% of infiltrating ductal
carcinoma (IDC) node negative and 48.8% of infiltrating lobular carcinoma node negative. In paired
samples, S100A4 protein was expressed in 13.5% of IDC node positive cases and 35.1% of matched
lymph node metastasis.
Conclusion: S100A4 protein expression appears widely expressed in early and advanced breast
cancer stages compared with normal breast. Our study suggests S100A4 may play a role in breast
cancer progression and may prove to be an independent marker of breast cancer which appears
to be down regulated in more advanced stages of breast cancer.
Background
Breast cancer is still the most common public health prob-
lem in women worldwide [1]. Cancer cells may invade the
surrounding by tissue remodeling and angiogenesis [2-7].
They may spread through the bloodstream and lymphatic
system to other parts of the body [2-7]. The majority of
invasive breast cancer from the epithelium of lobules and
ducts of the glands [8-21]. Metastasis is considered as the
spreading of tumor cells from the primary neoplasm to
distant sites [22,23]. In spite of significant advancement
in early diagnosis, surgical intervention as well as local
and systemic adjuvant therapies, the majority of cancer
deaths are attributable to metastasis that are resistant to
available therapies [22].
The metastasis process is not a random process but consist
of a complex series of linked and interrelated steps involv-
ing multiple host-tumor interaction [24]. Many proteins
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including proteases, adhesion molecules, angiogenesis,
and growth factor are involved in metastasis [25]. There-
fore, understanding the gene and protein expression
changes in metastatic cancer cells and nearby cells of the
microenvironment may aid in early diagnosis and thera-
peutic intervention. During the last decade, considerable
progress has been made in understanding these changes at
the molecular level. In fact most deaths of women with
breast cancer arise not as a result of primary tumor but
from its metastatic spread to distant sites in the body
[26,27]. Once spread and secondary masses are formed,
breast cancers are usually incurable [28]. Yet a sensitive
and reliable method for early metastasis in breast cancer is
still not available.
Breast cancer is considered to be a systemic disease this
would mean that the most breast carcinoma metastasize
before diagnosis of the primary lesion [29]. Therefore,
early detection of metastasized lesion and identification
of more effective therapeutic modalities for metastatic dis-
ease are necessities if the prognosis for patients with
advanced breast cancer is to improve.
The S100 gene family located on chromosome 1q21,
comprises more than 20 members whose protein
sequences encompass at least one EF-hand Ca++ binding
motif [30,31]. S100 is a 21 Kd highly acidic and water sol-
uble calcium binding protein [32]. S100A4 gene occurs in
cluster of 13 S100 genes on chromosome 1 [33], which
are also often amplified in cancer of the breast and which
contains jumping elements [34]. The expression of indi-
vidual family members is not permanent for all tissues
and appears to be an element of tissue specific expression.
S100A4 is composed of an alpha and beta chain with
molecular weight of 10 – 12 Kd [35]. It is a small molecule
and can pass through the nuclear pores without any active
transport mechanism being involved. S100A4 binds and
inhibits phosphorylation of the p53 C-terminal peptide
by protein kinase C. The tumor suppressor protein p53
has also been identified as an S100A4 interacting protein
and may provide a link between S100A4 and apoptosis
[36]. p53 is a critical tumor suppressor that is involved in
most if not all tumorigenesis. Almost 30–50% of breast
cancers contain a p53 mutation [37]. Other reported
S100A4 interacting proteins include tropomyosin,
methionine aminopeptidase, and CCN3 (cysteine-rich
61/connective tissue growth factor/nephroblastoma over-
expressed) [38-40].
Studies to determine the mechanistic basis for S100A4
function have shown a potential role for S100A4 in sev-
eral different facts of tumor progression including motil-
ity, invasion, and apoptosis [[36,41], and [42]]. It has also
been reported that extracelluar secreted S100A4 can affect
cell differentiation and migration [42-44]. Elevated levels
of immunocytochemically detected S100A4 are associated
with the more malignant carcinomatous regions of the
primary tumor and with liver metastasis [45]. An increase
in S100A4 protein expression has been correlated with a
worse prognosis for patients with different types of cancer
including colorectal, gallbladder, bladder, esophageal,
breast, and non small lung cancer [46-52]. The main pur-
pose of the study was to find the expression pattern of
S100A4 proteins in different types of breast cancer with or
without lymph node involvement and to determine its
role in breast cancer using tissue microarray.
Methods
Formalin-fixed paraffin-embedded tissue microarrays
from 188 lymph node negative breast cancer patients, 50
breast cancer patients with lymph node metastasis (50
malignant tissues and 50 matched lymph node tissue
cores with metastasis) and 8 normal breast tissue cores
were analyzed by immunohistochemistry for the expres-
sion S100A4 protein. Included in this study were patients
with infiltrating ductal carcinoma, infiltrating lobular car-
cinoma, normal breast tissue and lymph node metastasis.
The final number was 122 tissue cores of node negative
infiltrating ductal carcinoma, 41 node negative infiltrat-
ing lobular carcinoma, seven normal breast tissue, 40
node positive (38 infiltrating ductal carcinoma, 2 infiltrat-
ing lobular carcinoma) and 46 tissue cores of lymph node
metastasis. We did not evaluate infiltrating lobular carci-
noma node positive because of the low sample size (2
cases). Forty six tissue cores were excluded from statistics
because very little cancer cells or no breast cancer tissue
were seen. The total number after exclusion was 254 tissue
cores (37 matched tissues) of 216 patients.
Immunohistochemistry (IHC)
Rabbit Anti-Human polyclonal primary antibody against
S100A4 protein (Code No. A5114, from DakoCytoma-
tion, Denmark) was used on deparaffinized tissue micro-
array slides (Cat. No. BR 2001, BR 1001 from Biomax,
USA). A secondary detection system (DAKO Envision)
enhanced with conjugated polymer was used to bind with
the primary antibody. DAB chromogen was used for per-
manent color development and detection under micro-
scope.
The percentage of carcinoma cells with cytoplasmic/mem-
branous/nuclear staining was recorded on each specimen
at 200× magnification, using light microscope. The
expression of S100A4 was scored in all tumors as: positive
≥ 5% and negative < 5% stained cells. Also the intensity of
staining was categorized into three groups: weak, moder-
ate and strong. This was ascertained by a single qualified
pathologist.Cancer Cell International 2008, 8:12 http://www.cancerci.com/content/8/1/12
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A tissue section of breast cancer was used as positive con-
trol for S100A4. Rabbit IgG isotype (Sigma-Aldrich, USA)
was used instead of primary antibody in the immunohis-
tochemical technique on a tissue section each of breast
cancer and normal breast as negative control (Figure 1).
The tissue microarray slides were placed on hot plate at
60°C for 30 minutes. The slides were immersed in two
changes of xylene. Slides were then immersed in 3 differ-
ent concentrations of ethanol. Slides were rinsed with dis-
tilled water to remove ethanol. The slides were then
placed in target retrieval solution EDTA buffer pH 9.0
(DAKO) and heated on microwave. Slides were allowed to
cool at room temperature and rinsed with Tris Buffered
saline (TBS) mixed with tween 20. Slides were covered
with peroxidase blocking solution (DAKO), followed by
rinsing with TBS buffer mixed with tween 20. Then 200 μl
of primary antibody (dilution 1:200) was added on the
tissue microarray slides, followed by rinsing with TBS
mixed with tween 20. Two drops of DAKO Envision/HRP,
Rabbit/Mouse (secondary antibody) were added on the
slides, followed by rinsing with TBS mixed with tween 20.
After that DAB substrate (DAKO) was added on section
slides followed by rinsing, immersion into hematoxylin
and 4 different concentrations of ethanol. After that slides
were immersed in two changes of xylene and cover
slipped. All incubation steps after heat induced epitope
retrieval were carried at room temperature.
Results
The S100A4 protein was expressed in the cell cytoplasm
without evidence of nuclear staining.
There were a total of 122 cases of infiltrating ductal carci-
noma node negative and 41 cases of infiltrating lobular
carcinoma node negative. Infiltrating ductal carcinoma
node positive consisted of 38 cases. Thirty seven cases had
paired primary infiltrating ductal carcinoma tissue with its
matched lymph node core. There were also 9 cases of
unrelated lymph node cores containing metastatic depos-
its.
A positive expression of S100A4 was observed in 45.1%
(55/122) cases of infiltrating ductal carcinoma node neg-
ative (Figure 2) and 48.8% (20/41) cases of infiltrating
lobular carcinoma node negative (Figure 3). S100A4
staining was not observed in normal breast tissues (Figure
4).
Five of 37 (13.5%) cases in the paired samples (primary
breast carcinoma and matched lymph nodes) showed
presence of S100A4 protein in the primary site, while 13/
37 (35.1%) cases showed S100A4 in lymph node (Figure
5).
It was observed that 12 of 17 (70.5%) paired cases (pri-
mary breast cancer with matched lymph node) showed
expression of S100A4 in the lymph node metastasis with
absent expression in the primary site. Four (23.5%) cases
showed S100A4 expression in the primary breast carci-
noma with absent expression in its matched lymph node
metastasis. One case showed S100A4 expression in both
sites.
Discussion
Cancer is a disease or disorder characterized by uncon-
trolled growth (division) of the cells [53-55] and their
Negative control, S100A4 protein immunohistochemical  staining in breast cancer tissue, showing absent staining  (×200) Figure 1
Negative control, S100A4 protein immunohisto-
chemical staining in breast cancer tissue, showing 
absent staining (×200).
Positive expression of S100A4 within infiltrating ductal carci- noma node negative (×200) Figure 2
Positive expression of S100A4 within infiltrating duc-
tal carcinoma node negative (×200).Cancer Cell International 2008, 8:12 http://www.cancerci.com/content/8/1/12
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ability to invade other organ or tissue, either by invasion
or metastasis [54-56]. Although there are many types of
cancer, all cancer types begin with uncontrolled growth of
abnormal single cells in the body [55]. Oncogene ampli-
fication usually occurs late in tumor progression and cor-
relates well with aggressiveness of tumor [57]. The
function of the S100A4 protein and its role in metastasis
is unclear at present. It has been reported that S100A4
may affect the function of cytoskeletal proteins including
actin and non muscle myosin [58,59] so it is possible that
S100A4 may regulate cell shape and or motility. It was
reported that over expression of S100A4 protein is closely
correlated with many functions for tumor aggressiveness,
such as lymph node metastasis [60].
In the present study, S100A4 protein expression was
examined by immunohistochemistry in infiltrating duc-
tal, infiltrating lobular carcinoma and lymph node metas-
tasis and their relation to tumor promotion and
progression. Positive expression of S100A4 was observed
in 45.1% of the infiltrating ductal carcinoma node nega-
tive cases, while in infiltrating lobular carcinoma with
node negative, the expression of S100A4 protein was
observed in 48.8%. This shows that S100A4 has a similar
expression level in both infiltrating ductal carcinoma and
infiltrating lobular carcinoma with node negative.
S100A4 staining was not observed in normal breast tis-
sues. S100A4 was expressed in a higher percentage in
breast cancer tissue compared to normal tissue which
showed direct correlation of S100A4 protein in infiltrat-
ing breast cancer node negative. This suggests that S100A4
is over expressed in infiltrating breast carcinoma com-
pared to normal breast. Positive expression of S100A4
protein was observed only in 13.5 % of cases of infiltrat-
ing ductal carcinoma node positive while positive expres-
sion of S100A4 protein was observed in 35.1% of
matched lymph node metastasis. These results showed
there was a decrease in expression of S100A4 in infiltrat-
ing ductal carcinoma node positive (13.5%) compared
with IDC node negative (45.1% positive staining), but
interestingly there is an increase of expression of S100A4
protein at metastatic lymph node site. This suggests
S100A4 may play a role in advanced breast cancer espe-
cially with lymph node metastasis. It was also interesting
to note that the expression was seen in one site i.e. either
primary tumor or its metastatic lymph node only.
Positive expression of S100A4 within infiltrating lobular car- cinoma node negative (×200) Figure 3
Positive expression of S100A4 within infiltrating lob-
ular carcinoma node negative (×200).
Negative expression of S100A4 protein within normal breast  tissues (×200) Figure 4
Negative expression of S100A4 protein within nor-
mal breast tissues (×200).
Positive expression of S100A4 within matched lymph node  metastasis (×200) Figure 5
Positive expression of S100A4 within matched lymph 
node metastasis (×200).Cancer Cell International 2008, 8:12 http://www.cancerci.com/content/8/1/12
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The majority (70%, 12/17) of paired samples showed that
when there was a positive expression of S100A4 protein in
metastatic lymph node, there was associated negative
expression in the primary tumor (infiltrating ductal carci-
noma) of the same patient. One case showed positive
expression in both primary tumor and its metastatic
lymph node at the same time. This was comparable with
another study which showed that S100A4 over expression
directly correlated with tumor progression [60]. This
study found that S100A4 was expressed in more cases of
metastatic lymph node (35.1% cases) compared to
matched infiltrating ductal carcinoma node positive
(13.5% cases). These results show that there was a
decrease expression of S100A4 protein in the primary
tumor and increase expression in the metastatic lymph
node for the same patient. This suggests that S100A4 is
highly expressed in newly growing cancer either in the pri-
mary or metastatic sites. S100A4 protein was expressed in
the cytoplasm of node negative IDC and ILC, whereas
decreased in more advanced cancer (node positive). The
reduction in S100A4 expression in the primary site may
probably be related to cancer cells in the process of migra-
tion to distant sites.
Conclusion
In conclusion S100A4 protein expression appears to be
expressed widely in early and advanced stages of breast
cancer compared with normal breast. This study indicates
a complex role of S100A4 in breast cancer of different
types and stages. The difference in the expression of
S100A4 protein suggests it may be useful as an independ-
ent marker of breast cancer which appears to be down reg-
ulated in more advanced stages of breast cancer. However
a larger study with more ILC and metastatic cases may
clarify the role and function of S100A4 in breast cancer
progression.
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